Erythrocyte C3b receptors (E-CR1) were assayed by ELISA in 16 patients with acute viral hepatitis. In 13 patients with hepatitis type A, type B, or type non-A non-B, the E-CR1 level was significantly lower in the acute phase than in healthy controls, and recovered in the convalescent phase. The E-CR1 levels in 3 patients with non-A, non-B hepatitis remained below the mean level of the healthy controls. These findings suggest that the E-CR1 level fluctuates in acute viral hepatitis, and that itcontinues to be reduced in some patients with non-A non-B acute hepatitis.
Introduction
In 1953, Nelsonl) found that antigen-antibody complexes adhere to primate erythrocytes via complement, and Nishioka et al. 2) showed that this adhesion is due to bindingof the third complement component to C3b receptors (CR1s) on the surface of human erythrocytes. In 1983, Cornacoff et al. 3) showed that immune complexes (ICs) injected intravenously into baboons immediately bound to erythrocytes but that ICs bound to erythrocytes had been completely eliminated in the hepatic vein. From these reports, the erythrocyte-CR1 (E-CR1) is considered to be involved in the transport and elimination of ICs.
The presence of ICs has been reported also in acute viral hepatitis4) and various liver diseases5,6). The presence of ICs is liver diseases is considered to be reflected by the E-CR1 level, but, to our knowledge, there has been only one report of E-CR1 assay in liver diseases, that by Kondo et al.7 In the present study, we serially determined the E-CR1 level in patients with acute viral hepatitis byELISA3) and studied its clinical significance in this disease.
Materials and Methods
Subjects
The subjects were 16 patients with acute viral hepatitis who were admitted toour department or related hospitals between June 1989 and May 1990 and were available for follow-up studies and serial blood sampling. As shown in Table 1 , they consisted of 6 patients with acute hepatitis type A (AHA) definitively diagnosed by the positive for IgM anti-HAY antibody, 3 patients with acute hepatitis type B (AHB) in whom HBs antigen was positive and IgM class anti-HBc antibody was increased and HBs antigen disappeared during the course, and 7 patients with non-A non-B acute hepatitis (AHNANB) in whom AHA and AHB, alcohol-or drug-induced hepatic injury, and primary infection with cytomegalvorius or Epstein-Barr Reprint requests: Haruo MURAOKA, The Second Department of Medicine, Kurume University School of Medicine, 67
Asahi-machi, Kurume-shi, Fukuoka 830 Japan erythrocyte suspension was between 1.25 X 106/well and 5.0 X 106/well, both Hb concentration and the E-CR1 level reached a plateau, showing no significant changes in the O.D. value. These results suggest that the maximum number of solid-phase erythrocytes in each well is 1.25 X 106. Therefore, the erythrocyte suspension (5 X 106) used in this study contained more than an adequate number of erythrocytes that would be changed to the solid phase in the well. These results also suggest that changes in the E-CR1 level can be compared among samples when the number of erythrocytes per well that change to the solid phase is constant. 3 . Statistical analysis Data were tested for significant differences by studient's t-test. (Table 2) In the 8 healthy individuals, the E-CR1 levels were distributed in a range of56.3-100% (80.7 + 13.9%).
Results

E-CR1 level in healthy controls
Changes in the E-CR1 level in the course of hepatitis (Figs. 2 and 3)
Changes in the mean sGPT level and the E-CR1 level in the 6 AHA patients and the 3 AHB patients are shown in Fig. 2 . The sCPT level showed a monophasic peak and the expected recovery thereafter in both Table 2 Erythrocyte CR1 levels in healthy controls. AHA and AHB patients. The E-CR1 level decreased to 49.7-68.9% (58.0 + 6.2%) in the acute phase 2-4 weeks after the onset in AHA patients, but increased thereafter and reached 74.6-108% (84.3 + 14.8%) in the convalescent phase 7-8 weeks after the onset. The E-CR1 level showed similar changes in AHB patients; it decreased to 30.5, 55.4, and 68.0% (mean 51.3%) in 3 patients 2-4 weeks after the onset but increased to 72.3, 112.8, and 117.0%, respectively (mean 100.7%) 6-9 weeks after the onset. Fig. 3 shows changes in the E-CR1 level in all 7 AHNANB patients. Unlike AHA or AHB, there was no particular tendency, and the changes in 4 patients solid lines were similar to those in AHA and AHB patients. In one of these patients, the E-CR1 level increased after the onsetand reached 118% after 5 weeks.
In the other 3 of these patients, it temporarily decreased to 44.1, 69.2, and75.3% (mean 61.9%) after 2-4 weeks but increased to 83.4, 85.1, and 98.4%, respectively (mean 89.0%) after5-6 weeks. In the remaining 3 patients (broken lines), however, the E-CR1 level continued to be less than 70% except for a temporary increase to 75.6% in one of them. 3. Comparison of the E-CR1 levels in healthy controls and patients with hepatitis in various phaszes (Fig.  4) The maximum and minimum E-CR1 levels were compared in the 8 healthy controls and 7 hepatitis patients (3 with AHA, 1 with AHB, and 3 with AHNANB) in whom the E-CR1 level,followed from immediately after the onset, decreased in the acute phase and increased in the convalescent phase. In the patients, the E-CR1 levels at the onset, in the acute phase, and the convalescent stage were 90.0 + 15.6, 57.4 + 15.8, and 84.6 + 10.3%, respectively, being significantly reduced (p<0.01) in the acute phase as compared with 80.7 + 13.9% in the healthy controls. No significant differences were noted at the onset or in the convalescent phase. Discussion CR1 is present on erythrocytes, neutrophils, monocyte/macrophages, B-lymphocytes, some Tlymphocytes, and glomerular epithelial cells9). The mean number of E-CRls is 950/cell, far fewer than neutroplil or lymphocyte CR1s. However, as erythrocytes are more numerous, E-CRls account for more than 95% of all CRls in the blood flow, indicating the importance of E-CR1 inthe transport and elimination of ICs10). We therefore studied time-related changes in the E-CR1 level in patients with acute viral hepatitis, in which ICs are known to appear during the course of the disease4)-6).
In healthy controls, the E-CR1 level varied widely, from 56.3 to 100%. Holme et al." determined the number of E-CRls per erythrocyte in 56 normal individuals by RIA using anti-CR1 antibody and reported 335-8809 sites/cell, showing a wide variation as in our present study. Wilsonet al.12) obtained CR1 genes from normal individuals showing high, middle, and low E-CR1 levels and found that DNA fractions 7.4 Kb and 6.9 Kb,obtained by treating the genes with the restriction enzyme Hind III, corresponded to genotypes related to high and low CR1 densities.This suggests that the presence of E-CR1 is genetically regulated. The E-CR1 level in acute viral hepatitis patients was minimum in the acute phase 2-4 weeks after the onset in AHA and AHB patients but tended to return to the original level in the convalescent period.On the other hand,in 4 of the 7 AHNANB patients,it showed changes similar to those in AHA or AHB patients but remained below 70% in the remaining 3 patients.Of the former 4 AHNANB patients, the E-CR1 level did not decrease even in the acute phase and increased thereafter in one,but it decreased in the acute phase and increased in the convalescent phase in the other 3 as in AHA and AHB patients.In the latter 3 patients, on the other hand, it remained below 70% except for a temporary increase to 75.6% in one. Kondo et al.7) observed changes in the E-CR1 level in one patient with fulminant hepatitis,2 patients with drug-induced liver injury,and 2 patients with liver cirrhosis,and stated that the E-CR1 level continued to be low in the cirrhosis patients but decreased in the early stage of the disease and increased in the convalescent phase in those with fulminant hepatitis and drug-induced liver injury.These findings are consistent with our observations if the AHNANB patients who showed consistently low E-CR1 levels are excluded.
In this study,the E-CR1 levels in 7 acute viral hepatitis patients at the onset of the disease,in the acute phase,and in the convalescent phase were compared with those of 8 healthy controls.It was significantly lower in the patients than in the healthy controls in the acute phase.
There have been a number of reports on changes in the E-CR1 level in the clinical course of systemic lupus erythematosus(SLE)13)-16)and it has been shown to decrease in the active phase of the disease. Wilson et al.13) reported that the E-CR1 level is genetically determined,but other investigators consider it to be determined by acquired factors14)-16)on the basis that it is increased in the convalescent. Inada et al. 14) reported that the E-CR1 level and the ICs level are inversely related.Walport et al. 15 ) noted a rapid decrease in E-CR1 after transfusion of erythrocytes with high CR1 levels in patients with SLE complicated by hemolytic anemia, and suggested that the decrease in E-CR1 in this disease is due to blocking of E-CR1 by autoantibody to CR1 or ICs. In addition, Ross et al. 16) found that C3dg, a degradation product of C3b, was increased on the erythrocyte membrane when E-CRls were reduced. Since E-CR1 degrades C3b bound by ICs into C3c and C3dg in the presence of an inactivating factor17),they considered that increase in C3dg was due to its deposition secondary to the binding of E-CR1 by ICs. These observations suggest that the decrease in E-CR1 in SLE is a result of its blocking by ICs.
Concerning the time of the appearance of ICs in acute viral hepatitis, Aritaka4)studied its component immunoglobulin classes by Raji cell immunoassay,and noted that IgA and IgM class ICs appeared in the early stage of disease and disappeared within 6 weeks in most cases, but that IgG class ICs reached a peak level 3-6 weeks after the onset in AHA and in the same or slightly later period in AHB,and that no clear peak was noted in AHNANB.This coincidence of the decrease in E-CRls and the increase in ICs suggests a relationship between E-CRls and ICs.In addition,Thomas et al.51 measured ICs by the anti-complementary assay and the C lq binding assay in patients with acute and chronic liver diseases of varying etiologies. They noted the association of increased Clq binding with active inflammation in liver diseases and suggested that increased ICs may indicate that cells of the reticuloendotherial system are disturbed during episodes of acute hepatic necrosis.
From these findings,the significant decrease in the E-CR1 level in the acute phase of acute viral hepatitis is thought to be a phenomenon caused by blocking of E-CR1 by their binding with ICs,which are increased in the blood flow.Therefore,E-CR1 may be involved in the clearance of ICs not only in SLE but also in acute viral hepatitis.
Simultaneous measurement of the E-CR1 and blood IC levels and analysis of components of ICs that bind to E-CR1 are considered to be necessary in the future.
